Hjem
Per Eystein Lønnings bilde

Per Eystein Lønning

Professor
  • E-postPer.Lonning@uib.no
  • Telefon+47 55 97 20 10+47 55 97 20 27
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen

Professor Per Eystein Lønning har arbeidet sammenhengende innenfor kreftbehandling og forskning fra 1982. Han har fra 1990 vært overlege ved Kreftavdelingen, Haukeland Sykehus, og fra 1992 Professor ved Universitetet i Bergen.  Han leder Brystkreftgruppen ved Mohn kreftforskningslaboratorium. Gruppen, som i alt teller vel 20 medlemmer, arbeider hovedsakelig med brystkreft men og med andre kreftsykdommer, som tykktarmskreft og føflekkkreft. Gruppen består av forskere i Mohn Kreftforskningslaboratorium samt leger ved Kreftavdelingen, der flere i likhet med Lønning arbeider både med pasientbehandling og laboratorie-forskning. Lønning har arbeidet både med virkningsmekanismene for hormonell behandling samt cellegift ved brystkreft, og i tillegg arbeidet med kreftrisiko-faktorer. Hovedfeltet nå er mekanismer for resistens mot cellegift. 

Bøker
  • Lønning, Per Eystein; Sørlie, Therese; Børresen-Dale, Anne-Lise. 2005. Genomics in breast cancer - therapeutic implications. 8 sider.
Tidsskriftartikler
  • Aakko, Sofia; Straume, Anne Hege; Birkeland, Einar Elvbakken; Chen, Ping; Qiao, Xi; Lønning, Per Eystein; Kallio, Marko J. 2019. MYC-induced miR-203b-3p and miR-203a-3p control Bcl-xL expression and paclitaxel sensitivity in tumor cells. Translational Oncology. 12: 170-179. doi: 10.1016/j.tranon.2018.10.001
  • Bu, Dawei; Crewe, Clair; Kusminski, Christine M.; Gordillo, Ruth; Ghaben, Alexandra L.; Kim, Min; Park, Jiyoung; Deng, Hui; Xiong, Wei; Liu, Xiaozheng; Lønning, Per Eystein; Halberg, Nils; Rios, Adan; Chang, Yujun; Gonzalez, Anneliese; Zhang, Ningyan; An, Zhiqiang; Scherer, Philipp E. 2019. Human endotrophin as a driver of malignant tumor growth. JCI Insight. 4:e125094: 1-17. doi: 10.1172/jci.insight.125094
  • Margonis, Georgios Antonios; Buettner, Stefan; Andreatos, Nikolaos; Wagner, Doris; Sasaki, Kazunari; Barbon, Carlotta; Beer, Andrea; Kamphues, Carsten; Løes, Inger Marie; He, Jin; Pawlik, Timothy M.; Kaczirek, Klaus; Poultsides, George; Lønning, Per Eystein; Cameron, John L.; Mischinger, Hans Joerg; Aucejo, Federico N.; Kreis, Martin E.; Wolfgang, Christopher L.; Weiss, Matthew J. 2019. Prognostic factors change over time after hepatectomy for colorectal liver metastases: A multi-institutional, international analysis of 1099 patients. Annals of Surgery. 269: 1129-1137. doi: 10.1097/SLA.0000000000002664
  • Røsland, Gro Vatne; Dyrstad, Sissel Elisabeth; Tusubira, Deusdedit; Helwa, Reham; Tan, Tuan Zea; Lotsberg, Maria Lie; Pettersen, Ina Katrine Nitschke; Berg, Anna; Kindt, Charlotte; Hoel, Fredrik; Jacobsen, Kristine; Arason, Ari Jon; Engelsen, Agnete; Ditzel, Henrik J.; Lønning, Per Eystein; Krakstad, Camilla; Thiery, Jean Paul; Lorens, James; Knappskog, Stian; Tronstad, Karl Johan. 2019. Epithelial to mesenchymal transition (EMT) is associated with attenuation of succinate dehydrogenase (SDH) in breast cancer through reduced expression of SDHC. Cancer & Metabolism. doi: 10.1186/s40170-019-0197-8
  • Birkeland, Einar Elvbakken; Zhang, Shan; Poduval, Deepak; Geisler, Jürgen; Nakken, Sigve; Vodak, Daniel; Meza, Leonardo Zepeda; Hovig, Eivind; Myklebost, Ola; Knappskog, Stian; Lønning, Per Eystein. 2018. Patterns of genomic evolution in advanced melanoma. Nature Communications. 9:2665: 1-12. Publisert 2018-04-30. doi: 10.1038/s41467-018-05063-1
  • Borgen, Elin; Rypdal, Maria Christine; Sosa, Maria Soledad; Renolen, Anne; Schlichting, Ellen; Lønning, Per Eystein; Synnestvedt, Marit; Aguirre-Ghiso, Julio; Naume, Bjørn. 2018. NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. Breast Cancer Research. 20: 1-13. doi: 10.1186/s13058-018-1049-0
  • Deshwar, Amar; Margonis, Georgios Antonios; Andreatos, Nikolaos; Barbon, Carlotta; Wang, Jaeyun; Buettner, Stefan; Wagner, Doris; Sasaki, Kazunari; Beer, Andrea; Løes, Inger Marie; Pikoulis, Emmanouil; Damaskos, Christos; Garmpis, Nikolaos; Kamphues, Karsten; He, Jin; Kaczirek, Klaus; Poultsides, George; Lønning, Per Eystein; Mischinger, Hans Joerg; Aucejo, Federico N.; Kreis, Martin E.; Wolfgang, Christopher L.; Weiss, Matthew J. 2018. Double KRAS and BRAF mutations in surgically treated colorectal cancer liver metastases: An international, multi-institutional case series. Anticancer Research. 38: 2891-2895. doi: 10.21873/anticanres.12535
  • Di Leo, Angelo; Johnston, Stephen; Lee, Keun Seok; Ciruelos, Eva; Lønning, Per Eystein; Janni, Wolfgang; O'Regan, Ruth; Mouret-Reynier, Marie-Ange; Kalev, Dimitar; Egle, Daniel; Csöszi, Tibor; Bordonaro, Roberto; Decker, Thomas; Tjan-Heijnen, Vivianne C.G.; Blau, Sibel; Schirone, Alessio; Weber, Denis; El-Hashimy, Mona; Dharan, Bharani; Sellami, Dalila; Bachelot, Thomas. 2018. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology. 19: 87-100. doi: 10.1016/S1470-2045(17)30688-5
  • Knappskog, Stian; Gansmo, Liv Beathe; Lønning, Per Eystein. 2018. Association of rs2279744 and rs117039649 promoter polymorphism with the risk of gynaecological cancer: A meta-analysis of case-control studies. Medicine.
  • Lønning, Per Eystein; Berge, Elisabet Ognedal; Bjørnslett, Merete Pauline; Minsaas, Laura; Chrisanthar, Ranjan; Vetti, Hildegunn Høberg; Dulary, Cécile; Busato, Florence; Bjørneklett, Silje; Eriksen, Christine; Kopperud, Reidun Kristin; Axcrona, Ulrika; Davidson, Ben; Bjørge, Line; Evans, D. Gareth; Howell, Anthony; Salvesen, Helga; Janszky, Imre; Hveem, Kristian; Romundstad, Pål Richard; Vatten, Lars Johan; Tost, Jörg; Dørum, Anne; Knappskog, Stian. 2018. White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Annals of Internal Medicine. 168: 326-334. doi: 10.7326/M17-0101
  • Lønning, Per Eystein; Knappskog, Stian. 2018. BRCA1 methylation in newborns: Genetic disposition, maternal transfer, environmental influence, or by chance only? Clinical Epigenetics. 10. doi: 10.1186/s13148-018-0566-0
  • Margonis, Georgios Antonios; Buettner, Stefan; Andreatos, Nikolaos; Kim, Yuhree; Wagner, Doris; Sasaki, Kazunari; Beer, Andrea; Schwarz, Christoph; Løes, Inger Marie; Smolle, Maria; Kamphues, Carsten; He, Jin; Pawlik, Timothy M.; Kaczirek, Klaus; Poultsides, George; Lønning, Per Eystein; Cameron, John L.; Burkhart, Richard A.; Gerger, Armin; Aucejo, Federico N.; Kreis, Martin E.; Wolfgang, Christopher L.; Weiss, Matthew J. 2018. Association of BRAF mutations with survival and recurrence in surgically treated patients with metastatic colorectal liver cancer. JAMA Surgery. 153: 1-8. doi: 10.1001/jamasurg.2018.0996
  • Margonis, Georgios Antonios; Buettner, Stefan; Andreatos, Nikolaos; Wagner, Doris; Sasaki, Kazunari; Galjart, Boris; Kamphues, Carsten; Pawlik, Timothy M.; Poultsides, George; Kaczirek, Klaus; Lønning, Per Eystein; Verhoef, Cornelis; Kreis, Martin E.; Wolfgang, Christopher L.; Weiss, Matthew J. 2018. The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis. Journal of Surgical Oncology. 118: 1074-1080. doi: 10.1002/jso.25251
  • Yndestad, Synnøve; Austreid, Eilin; Skaftnesmo, Kai Ove; Lønning, Per Eystein; Eikesdal, Hans Petter. 2018. Divergent activity of the pseudogene PTENP1 in ER-positive and negative breast cancer. Molecular Cancer Research. 16: 78-89. doi: 10.1158/1541-7786.MCR-17-0207
  • Cheang, Maggie Chon U.; Bliss, Judith M.; Viale, Giuseppe; Speirs, Valerie; Palmieri, Carlo; Shaaban, Abeer M.; Lønning, Per Eystein; Morden, James P.; Porta, Nuria; Jassem, Jacek; van de Velde, Cornelis Johannes Hans; Rasmussen, Birgitte Bruun; Verhoeven, Didier M.; Bartlett, John M.S.; Coombes, Raoul Charles. 2017. Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast Cancer Research and Treatment. 168: 169-178. Publisert 2017-11-24. doi: 10.1007/s10549-017-4543-7
  • Gansmo, Liv Beathe; Bjørnslett, Merete Pauline; Halle, Mari Kyllesø; Salvesen, Helga; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Dørum, Anne; Lønning, Per Eystein; Knappskog, Stian. 2017. MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer. 17:97: 1-6. doi: 10.1186/s12885-017-3094-y
  • Gansmo, Liv Beathe; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Nik-Zainal, Serena; Lønning, Per Eystein; Knappskog, Stian. 2017. APOBEC3A/B deletion polymorphism and cancer risk. Carcinogenesis. 39: 118-124. doi: 10.1093/carcin/bgx131
  • Huun, Johanna; Gansmo, Liv Beathe; Mannsåker, Bård; Iversen, Gjertrud Titlestad; Sommerfelt-Pettersen, Jan; Øvrebø, Jan Inge; Lønning, Per Eystein; Knappskog, Stian. 2017. The Functional roles of the MDM2 splice variants P2-MDM2-10 and MDM2-∆5 in breast cancer cells. Translational Oncology. 10: 806-817. doi: 10.1016/j.tranon.2017.07.006
  • Huun, Johanna; Gansmo, Liv Beathe; Mannsåker, Bård; Iversen, Gjertrud Titlestad; Øvrebø, Jan Inge; Lønning, Per Eystein; Knappskog, Stian. 2017. Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. BMC Cell Biology. 18:17: 1-9. doi: 10.1186/s12860-017-0134-z
  • Huun, Johanna; Lønning, Per Eystein; Knappskog, Stian. 2017. Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines. Cell death discovery. 3. doi: 10.1038/cddiscovery.2017.26
  • Lønning, Per Eystein. 2017. Concerns about methodology of a trial investigating vaginal health during aromatase inhibitor therapy for breast cancer [3]. JAMA Oncology. 3: 1140-1140. doi: 10.1001/jamaoncol.2016.7123
  • Morden, James P.; Alvarez, Isabel; Bertelli, Gianfilippo; Coates, Alan S.; Coleman, Robert; Fallowfield, Lesley; Jassem, Jacek; Jones, Stephen; Kilburn, Lucy; Lønning, Per Eystein; Ortmann, Olaf; Snowdon, Claire; Van De Velde, Cornelis; Andersen, Jørn; Del Mastro, Lucia; Dodwell, David; Holmberg, Stig; Nicholas, Hanna; Paridaens, Robert; Bliss, Judith M.; Coombes, R. Charles. 2017. Long-term follow-up of The Intergroup Exemestane Study. Journal of Clinical Oncology. 35: 2507-2514. doi: 10.1200/JCO.2016.70.5640
  • Yates, Lucy R.; Knappskog, Stian; Wedge, David; Farmery, James H.R.; Gonzalez, Santiago; Martincorena, Inigo; Alexandrov, Ludmil B.; Van Loo, Peter; Haugland, Hans Kristian; Lilleng, Peer Kåre; Gundem, Gunes; Gerstung, Moritz; Pappaemmanuil, Elli; Gazinska, Patrycja; Bhosle, Shriram G.; Jones, David; Raine, Keiran; Mudie, Laura; Latimer, Calli; Sawyer, Elinor; Desmedt, Christine; Sotiriou, Christos; Stratton, Michael R.; Sieuwerts, Anieta M.; Lynch, Andy G.; Martens, John W.; Richardson, Andrea L.; Tutt, Andrew; Lønning, Per Eystein; Campbell, Peter J. 2017. Genomic evolution of breast cancer metastasis and relapse. Cancer Cell. 32: 169-184.e7. doi: 10.1016/j.ccell.2017.07.005
  • Yndestad, Synnøve; Austreid, Eilin; Knappskog, Stian; Chrisanthar, Ranjan; Lilleng, Peer Kåre; Lønning, Per Eystein; Eikesdal, Hans Petter. 2017. High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function. Breast Cancer Research and Treatment. 163: 177-190. doi: 10.1007/s10549-017-4160-5
  • Yndestad, Synnøve; Austreid, Eilin; Svanberg, Ida; Knappskog, Stian; Lønning, Per Eystein; Eikesdal, Hans Petter. 2017. Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. OncoTarget. 8: 41227-41241. doi: 10.18632/oncotarget.17167
  • Dowsett, Mitch; Lønning, Per Eystein; Davidson, Nancy E. 2016. Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer. Journal of Clinical Oncology. 34: 1580-1583. doi: 10.1200/JCO.2015.62.3728
  • Easton, Douglas F; Lesueur, Fabienne; Decker, Brennan; Michailidou, Kyriaki; Li, Jun; Allen, Jamie; Luccarini, Craig; Pooley, Karen A.; Shah, Mitul; Bolla, Manjeet K.; Wang, Qin; Dennis, Joe; Ahmad, Jamil; Thompson, Ella R.; Damiola, Francesca; Pertesi, Maroulio; Voegele, Catherine; Mebirouk, Noura; Robinot, Nivonirina; Durand, Geoffroy; Forey, Nathalie; Luben, Robert N.; Ahmed, Shahana; Aittomäki, Kristiina; Anton-Culver, Hoda; Arndt, Volker; Baynes, Caroline; Beckman, Matthias W.; Benitez, Javier; Van Den Berg, David; Blot, William J.; Bogdanova, Natalia V; Bojesen, Stig E.; Brenner, Hermann; Chang-Claude, Jenny; Chia, Kee Seng; Choi, Ji-Yeob; Conroy, Don M.; Cox, Angela; Cross, Simon S.; Czene, Kamila; Darabi, Hatef; Devilee, Peter; Eriksson, Mikael; Fasching, Peter A.; Figueroa, Jonine; Flyger, Henrik; Fostira, Florentia; García-Closas, Montserrat; Giles, Graham G.; Glendon, Gord; Gonzalez-Neira, Anna; Guenel, Pascal; Haiman, Christopher A.; Hall, Per; Hart, Steven N; Hartman, Mikael; Hooning, Maartje J.; Hsiung, Chia-Ni; Ito, Hidemi; Jakubowska, Anna; James, Paul A.; John, Esther M.; Johnson, Nichola; Jones, Michael; Kabisch, Maria; Kang, Daehee; Kosma, Veli-Matti; Kristensen, Vessela N.; Lambrechts, Diether; Li, Na; Myöhänen, Eija; Kemiläinen, Helena; Lindblom, Annika; Long, Jirong; Lophatananon, Artitaya; Lubinski, Jan; Mannermaa, Arto; Manoukian, Siranoush; Margolin, Sara; Matsuo, Keitaro; Meindl, Alfons; Mitchell, Gillian; Muir, Kenneth; Nevelsteen, Ines; Van Den Ouweland, Ans; Peterlongo, Paolo; Phuah, Sze Yee; Pylkäs, Katri; Rowley, Simone M; Sangrajrang, Suleeporn; Schmutzler, Rita K; Shen, Chen-Yang; Shu, Xiao-Ou; Southey, Melissa C; Surowy, Harald; Swerdlow, Anthony; Teo, Soo H; Tollenaar, Rob AEM; Tomlinson, Ian; Torres, Diana; Truong, Therese; Vachon, Celine; Verhoef, Senno; Wong-Brown, Michelle; Zheng, Wei; Zheng, Ying; Nevanlinna, Heli; Scott, Rodney J.; Andrulis, Irene L.; Wu, Anna H.; Hopper, John L.; Couch, Fergus J.; Winqvist, Robert; Burwinkel, Barbara; Sawyer, Elinor J.; Schmidt, Marjanka K.; Rudolph, Anja; Dörk, Thilo; Brauch, Hiltrud; Hamann, Ute; Neuhausen, Susan L.; Milne, Roger L.; Fletcher, Olivia; Pharoah, Paul D.P.; Campbell, Ian G.; Dunning, Alison M.; Le Calvez-Kelm, Florence; Goldgar, David E.; Tavtigian, Sean V.; Chenevix-Trench, Georgia; Kleivi, Kristine; Sauer, Torill; Riis, Margit; Grenaker, Grethe Irene; Bukholm, Ida Rashida Khan; Kiserud, Cecilie E.; Nord, Silje; Lønning, Per Eystein; Helland, Åslaug; Reinertsen, Kristin Valborg; Naume, Bjørn; Haakensen, Vilde Drageset; Ottestad, Lars; Kåresen, Rolf; Holmen, Marit Muri; Engebråten, Olav; Langerød, Anita; Schlichting, Ellen. 2016. No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: Implications for gene panel testing. Journal of Medical Genetics. 53: 298-309. doi: 10.1136/jmedgenet-2015-103529
  • Fleischer, Thomas; Klajic, Jovana; Aure, Miriam Ragle; Louhimo, Riku; Pladsen, Arne Valebjørg; Ottestad, Lars; Touleimat, Nizar; Laakso, Marko; Halvorsen, Ann Rita; Grenaker, Grethe Irene; Riis, Margit; Helland, Åslaug; Hautaniemi, Sampsa; Lønning, Per Eystein; Naume, Bjørn; Børresen-Dale, Anne-Lise; Tost, Jörg; Kristensen, Vessela N. 2016. DNA methylation signature (SAM40) identifies subgroups of the Luminal A breast cancer samples with distinct survival. OncoTarget. 8: 1074-1082. doi: 10.18632/oncotarget.13718
  • Flågeng, Marianne Hauglid; Larionov, Alexey; Geisler, Jürgen; Knappskog, Stian; Prestvik, Wenche S; Bjørkøy, Geir; Lilleng, Peer Kåre; Dixon, JM; Miller, William R.; Lønning, Per Eystein; Mellgren, Gunnar. 2016. Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers. Journal of Steroid Biochemistry and Molecular Biology. 165: 228-235. Publisert 2016-06-22. doi: 10.1016/j.jsbmb.2016.06.011
  • Gansmo, Liv Beathe; Bjørnslett, Merete Pauline; Halle, Mari Kyllesø; Salvesen, Helga; Dørum, Anne; Birkeland, Einar Elvbakken; Hveem, Kristian; Romundstad, Pål Richard; Vatten, Lars Johan; Lønning, Per Eystein; Knappskog, Stian. 2016. The MDM4 SNP34091 (rs4245739) C-allele is associated with increased risk of ovarian—but not endometrial cancer. Tumour Biology. 37: 10697-10702. doi: 10.1007/s13277-016-4940-2
  • Gansmo, Liv Beathe; Vatten, Lars Johan; Romundstad, Pål Richard; Hveem, Kristian; Ryan, Bríd M.; Harris, Curtis C.; Knappskog, Stian; Lønning, Per Eystein. 2016. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. OncoTarget. 7: 28637-28646. doi: 10.18632/oncotarget.8705
  • Helwa, Reham; Gansmo, Liv Beathe; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Ryan, Bríd M.; Harris, Curtis C.; Lønning, Per Eystein; Knappskog, Stian. 2016. MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. Scientific Reports. 6. 8 sider. doi: 10.1038/srep33153
  • Knappskog, Stian; Leirvaag, Beryl; Gansmo, Liv Beathe; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Lønning, Per Eystein. 2016. Prevalence of the CHEK2 R95* germline mutation. Hereditary Cancer in Clinical Practice. 14. 4 sider. doi: 10.1186/s13053-016-0059-0
  • Løes, Inger Marie; Immervoll, Heike; Sorbye, Halfdan; Angelsen, Jon-Helge; Horn, Arild; Knappskog, Stian; Lønning, Per Eystein. 2016. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. International Journal of Cancer. 139: 647-656. doi: 10.1002/ijc.30089
  • Sveen, Anita; Løes, Inger Marie; Alagaratnam, Sharmini; Nilsen, Gro; Høland, Maren; Lingjærde, Ole Christian; Sorbye, Halfdan; Berg, Kaja Christine Graue; Horn, Arild; Angelsen, Jon-Helge; Knappskog, Stian; Lønning, Per Eystein; Lothe, Ragnhild A. 2016. Intra-patient inter-metastatic genetic heterogeneity in colorectal cancer as a key determinant of survival after curative liver resection. PLoS Genetics. 12:e1006225. 22 sider. doi: 10.1371/journal.pgen.1006225
  • Tambe, Mahesh Balasaheb; Pruikkonen, Sofia; Mäki-Jouppila, Jenni Heidi Eveliina; Chen, Ping; Elgaaen, Bente Vilming; Straume, Anne Hege; Huhtinen, Kaisa; Carpén, Olli; Lønning, Per Eystein; Davidson, Ben; Hautaniemi, Sampsa; Kallio, Marko Johannes. 2016. Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel. OncoTarget. 7: 12267-12285. doi: 10.18632/oncotarget.7860
  • Flågeng, Marianne Hauglid; Knappskog, Stian; Gjerde, Jennifer; Lønning, Per Eystein; Mellgren, Gunnar. 2015. Estrogens correlate with PELP1 expression in ER positive breast cancer. PLOS ONE. 10:e0134351. 12 sider. doi: 10.1371/journal.pone.0134351
  • Gansmo, Liv Beathe; Knappskog, Stian; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Lønning, Per Eystein. 2015. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. International Journal of Cancer. 137: 96-103. doi: 10.1002/ijc.29358
  • Gansmo, Liv Beathe; Romundstad, Pål Richard; Birkeland, Einar Elvbakken; Hveem, Kristian; Vatten, Lars Johan; Knappskog, Stian; Lønning, Per Eystein. 2015. MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk. Cancer Medicine. 4: 1901-1907. doi: 10.1002/cam4.555
  • Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; de Faveri, Elise Norheim; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein. 2015. Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. 9: 1553-1564. doi: 10.1016/j.molonc.2015.04.008
  • Lauss, Martin; Haq, Rizwan; Cirenajwis, Helena; Phung, Bengt; Harbst, Katja; Staaf, Johan; Rosengren, Frida; Holm, Karolina; Aine, Mattias; Jirström, Karin; Borg, Åke; Busch, Christian; Geisler, Jürgen; Lønning, Per Eystein; Ringnér, Markus; Howlin, Jillian; Fisher, David E; Jönsson, Göran. 2015. Genome-wide DNA methylation analysis in melanoma reveals the importance of CpG methylation in MITF regulation. Journal of Investigative Dermatology. 135: 1820-1828. doi: 10.1038/jid.2015.61
  • Lauss, Martin; Ringnér, Markus; Karlsson, Anna; Harbst, Katja; Busch, Christian; Geisler, Jürgen; Lønning, Per Eystein; Staaf, Johan; Jönsson, Göran. 2015. DNA methylation subgroups in melanoma are associated with proliferative and immunological processes. BMC Medical Genomics. 8:73: 1-11. doi: 10.1186/s12920-015-0147-4
  • Løes, Inger Marie; Immervoll, Heike; Angelsen, Jon-Helge; Horn, Arild; Geisler, Jürgen; Busch, Christian; Lønning, Per Eystein; Knappskog, Stian. 2015. Performance comparison of three BRAF V600E detection methods in malignant melanoma and colorectal cancer specimen. Tumour Biology. 36: 1003-1013. doi: 10.1007/s13277-014-2711-5
  • Lønning, Per Eystein. 2015. Normal breast tissue estrogen levels. Maturitas. 81: 327. doi: 10.1016/j.maturitas.2015.03.005
  • Lønning, Per Eystein. 2015. Estradiol measurement in translational studies of breast cancer. Steroids. 99: 26-31. doi: 10.1016/j.steroids.2014.08.008
  • Myklebost, Ola; Lothe, Ragnhild A; Gjertsen, Bjørn Tore; Lønning, Per Eystein. 2015. Bør hver kreftpasient bli et eget forskningsprosjekt? Aftenposten (morgenutg. : trykt utg.). Publisert 2015-08-12.
  • Speirs, Valerie; Viale, Giuseppe; Mousa, Kelly; Palmieri, Carlo; Reed, Sadie N.; Nicholas, Hanna; Cheang, Maggie; Jassem, Jacek; Lønning, Per Eystein; Kalaitzaki, Eletheria; Van de Velde, Cornelis J.H.; Rasmussen, Birgitte Bruun; Verhoeven, Didier M.; Shaaban, Abeer M.; Bartlett, John M.S.; Bliss, Judith M.; Coombes, Raoul Charles. 2015. Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES. Annals of Oncology. 26: 1890-1897. doi: 10.1093/annonc/mdv242
  • Yates, Lucy R.; Gerstung, Moritz; Knappskog, Stian; Desmedt, Christine; Gundem, Gunes; Van Loo, Peter; Aas, Turid; Alexandrov, Ludmil B.; Larsimont, Denis; Davies, Helen; Li, Yilong; Ju, Young Seok; Ramakrishna, Manasa; Haugland, Hans Kristian; Lilleng, Peer Kåre; Nik-Zainal, Serena; McLaren, Stuart; Butler, Adam; Martin, Sancha; Glodzik, Dominic; Menzies, Andrew; Raine, Keiran; Hinton, Jonathan; Jones, David; Mudie, Laura J.; Jiang, Bing; Vincent, Delphine; Greene-Colozzi, April; Adnet, Pierre-Yves; Fatima, Aquila; Maetens, Marion; Ignatiadis, Michail; Stratton, Michael R.; Sotiriou, Christos; Richardson, Andrea L.; Lønning, Per Eystein; Wedge, David C.; Campbell, Peter J. 2015. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nature Medicine. 21: 751-759. doi: 10.1038/nm.3886
  • Austreid, Eilin; Lønning, Per Eystein; Eikesdal, Hans Petter. 2014. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy. 15: 681-700. doi: 10.1517/14656566.2014.885952
  • Eikesdal, Hans Petter; Knappskog, Stian; Aas, Turid; Lønning, Per Eystein. 2014. TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. Acta Oncologica. 53: 1347-1355. doi: 10.3109/0284186X.2014.922215
  • Folkerd, Elizabeth J.; Lønning, Per Eystein; Dowsett, Mitch. 2014. Interpreting plasma estrogen levels in breast cancer: Caution needed. Journal of Clinical Oncology. 32: 1396-1400. doi: 10.1200/JCO.2013.53.9411
  • Klajic, Jovana; Busato, Florence; Edvardsen, Hege; Touleimat, Nizar; Fleischer, Thomas; Bukholm, Ida Rashida Khan; Børresen-Dale, Anne-Lise; Lønning, Per Eystein; Tost, Jörg; Kristensen, Vessela N. 2014. Dnamethylation status of key cell-cycle regulators such as CDKNA2/P16 and CCNA1 correlates with treatment response to doxorubicin and 5-fluorouracil in locally advanced breast tumors. Clinical Cancer Research. 20: 6357-6366. doi: 10.1158/1078-0432.CCR-14-0297
  • Knappskog, Stian; Gansmo, Liv Beathe; Dibirova, Khadizha; Metspalu, Andres; Cybulski, Cezary; Peterlongo, Paolo; Aaltonen, Lauri; Vatten, Lars Johan; Romundstad, Pål Richard; Hveem, Kristian; Devilee, Peter; Evans, Gareth D; Lin, Dongxin; Van Camp, Guy; Manolopoulos, Vangelis G; Osorio, Ana; Milani, Lili; Ozcelik, Tayfun; Zalloua, Pierre; Mouzaya, Francis; Bliznetz, Elena; Balanovska, Elena; Pocheshkova, Elvira; Kucinskas, Vaidutis; Atramentova, Lubov; Nymadawa, Pagbajabyn; Titov, Konstantin; Lavryashina, Maria; Yusupov, Yuldash; Bogdanova, Natalia; Koshel, Sergey; Zamora, Jorge; Wedge, David C.; Charlesworth, Deborah; Dörk, Thilo; Balanovsky, Oleg; Lønning, Per Eystein. 2014. Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). OncoTarget. 5: 8223-8234.
  • Knappskog, Stian; Lønning, Per Eystein. 2014. MDM2 SNP309 and risk of cervical cancer. Tumour Biology. 35: 6185-6186. doi: 10.1007/s13277-014-1910-4
  • Knappskog, Stian; Lønning, Per Eystein. 2014. MDM2 SNP309 and risk of cervical cancer. Tumour Biology. doi: 10.1007/s13277-014-1910-4
  • Knappskog, Stian; Lønning, Per Eystein. 2014. MDM2 SNP309 and risk of endometrial cancer. Tumour Biology. doi: 10.1007/s13277-014-2244-y
  • Lønning, Per Eystein; Haynes, Benjamin P.; Dowsett, Mitch. 2014. Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. European Journal of Cancer. 50: 1055-1064. doi: 10.1016/j.ejca.2014.01.007
  • Russnes, Hege Elisabeth Giercksky; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Lingjærde, Ole Christian. 2014. The multitude of molecular analyses in cancer: the opening of Pandora’s box. Genome Biology. 15:447. 7 sider. doi: 10.1186/s13059-014-0447-6
  • Straume, Anne Hege; Knappskog, Stian; Lønning, Per Eystein. 2014. Effects of SNP variants in the 17β-HSD2 and 17β-HSD7 genes and 17β-HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology. 143: 192-198. doi: 10.1016/j.jsbmb.2014.02.003
  • Berge, Elisabet Ognedal; Huun, Johanna; Lillehaug, Johan R.; Lønning, Per Eystein; Knappskog, Stian. 2013. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin. Biochimica et Biophysica Acta - General Subjects. 1830: 2790-2797. doi: 10.1016/j.bbagen.2012.12.004
  • Birkeland, Einar Elvbakken; Busch, Christian; Berge, Elisabet Ognedal; Geisler, Jürgen; Jonsson, Göran; Lillehaug, Johan R.; Knappskog, Stian; Lønning, Per Eystein. 2013. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clinical and Experimental Metastasis. 30: 867-876. doi: 10.1007/s10585-013-9587-4
  • Flågeng, Marianne Hauglid; Knappskog, Stian; Haynes, Ben P.; Lønning, Per Eystein; Mellgren, Gunnar. 2013. Inverse regulation of EGFR/HER1 and HER2-4 in normal and malignant human breast tissue. PLOS ONE. 8. 12 sider. doi: 10.1371/journal.pone.0074618
  • Klajic, Jovana; Fleischer, Thomas; Dejeux, Emelyne; Edvardsen, Hege; Wärnberg, Fredrik; Bukholm, Ida Rashida Khan; Lønning, Per Eystein; Solvang, Hiroko Kato; Børresen-Dale, Anne-Lise; Tost, Jörg; Kristensen, Vessela N. 2013. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer. 13. 12 sider. doi: 10.1186/1471-2407-13-456
  • Knappskog, Stian; Lønning, Per Eystein. 2013. MDM2 SNP309 and risk of endometrial cancer. Polish Journal of Pathology. 64: 69-70. doi: 10.5114/PJP.2013.34607
  • Lønning, Per Eystein. 2013. Lapatinib in early breast cancer-questions to be resolved. The Lancet Oncology. 14: 11-12. doi: 10.1016/S1470-2045(12)70571-5
  • Lønning, Per Eystein; Eikesdal, Hans Petter. 2013. Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved. Endocrine-Related Cancer. 20: R183-R201. doi: 10.1530/ERC-13-0099
  • Lønning, Per Eystein; Knappskog, Stian. 2013. Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene. 32: 5315-5330. doi: 10.1038/onc.2013.48
  • Tahiri, Andliena; Røe, Kathrine; Ree, Anne Hansen; de Wijn, Rik; Risberg, Karianne; Busch, Christer; Lønning, Per Eystein; Kristensen, Vessela N.; Geisler, Jürgen. 2013. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma. PLOS ONE. 8. doi: 10.1371/journal.pone.0072692
  • Arnes, Jarle; Stefansson, Ingunn Marie; Straume, Oddbjørn; Baak, Jan P.A.; Lønning, Per Eystein; Foulkes, William D.; Akslen, Lars A. 2012. Vascular proliferation is a prognostic factor in breast cancer. Breast Cancer Research and Treatment. 133: 501-510. doi: 10.1007/s10549-011-1785-7
  • Bjørnslett, Merete Pauline; Knappskog, Stian; Lønning, Per Eystein; Dørum, Anne. 2012. Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers. BMC Cancer. 12. 6 sider. doi: 10.1186/1471-2407-12-454
  • Bliss, Judith M.; Kilburn, Lucy S.; Coleman, Robert E.; Forbes, John F.; Coates, Alan S.; Jones, Stephen E.; Jassem, Jacek; Delozier, Thierry; Andersen, Jørn; Paridaens, Robert; Van de Velde, Cornelis J.H.; Lønning, Per Eystein; Morden, James; Reise, Justine; Cisar, Laura; Menschik, Thomas; Coombes, R. Charles. 2012. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. Journal of Clinical Oncology. 30: 709-717. doi: 10.1200/JCO.2010.33.7899
  • Cao, Maria Dung; Döpkens, Mailin; Krishnamachary, Balaji; Vesuna, Farhad; Gadiya, Mayur M.; Lønning, Per Eystein; Bhujwalla, Zaver M.; Gribbestad, Ingrid S; Glunde, Kristine. 2012. Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR in Biomedicine. 25: 1033-1042. doi: 10.1002/nbm.2766
  • Cao, Maria Dung; Giskeødegård, Guro F.; Bathen, Tone Frost; Sitter, Beathe; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2012. Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy. BMC Cancer. 12. 11 sider. doi: 10.1186/1471-2407-12-39
  • Cao, Maria Dung; Sitter, Beathe; Bathen, Tone Frost; Bofin, Anna M.; Lønning, Per Eystein; Lundgren, Steinar; Gribbestad, Ingrid S. 2012. Predicting long-term survival and treatment response in breast cancer patients receiving neoadjuvant chemotherapy by MR metabolic profiling. NMR in Biomedicine. 25: 369-378. doi: 10.1002/nbm.1762
  • Knappskog, Stian; Chrisanthar, Ranjan; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Leirvaag, Beryl; Miletic, Hrvoje; Lønning, Per Eystein. 2012. Low expression levels of ATM may substitute for CHEK2/TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 14. 12 sider. doi: 10.1186/bcr3147
  • Knappskog, Stian; Gansmo, Liv Beathe; Romundstad, Pål Richard; Bjørnslett, Merete Pauline; Trovik, Jone; Sommerfelt-Pettersen, Jan; Løkkevik, Erik; Tollenaar, Rob A.E.M.; Seynaeve, Caroline; Devilee, Peter; Salvesen, Helga Birgitte; Dørum, Anne; Hveem, Kristian; Vatten, Lars Johan; Lønning, Per Eystein. 2012. MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. PLOS ONE. 7. 6 sider. doi: 10.1371/journal.pone.0036263
  • Knappskog, Stian; Lønning, Per Eystein. 2012. P53 and its molecular basis to chemoresistance in breast cancer. Expert opinion on therapeutic targets. 16: S23-S30. doi: 10.1517/14728222.2011.640322
  • Knappskog, Stian; Trovik, Jone; Marcickiewicz, Janusz; Tingulstad, Solveig; Staff, Anne Cathrine; Romundstad, Pål Richard; Hveem, Kristian; Vatten, Lars Johan; Salvesen, Helga Birgitte; Lønning, Per Eystein. 2012. SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer. European Journal of Cancer. 48: 1988-1996. doi: 10.1016/j.ejca.2011.10.024
  • Lønning, Per Eystein. 2012. Poor-prognosis estrogen receptor-positive disease: present and future clinical solutions. Therapeutic advances in medical oncology. Publisert 2012-05-04. doi: 10.1177/1758834012439338
  • Lønning, Per Eystein; Knappskog, Stian. 2012. Chemosensitivity and p53; new tricks by an old dog. Breast Cancer Research. 14: 325. Publisert 2012-11-06. doi: 10.1186/bcr3326
  • Mathiesen, Randi Margit Ruud; Borgen, Elin; Renolen, Anne; Løkkevik, Erik; Nesland, Jahn M; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Kvalheim, Gunnar; Lønning, Per Eystein; Naume, Bjørn. 2012. Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Research. 14. 13 sider. doi: 10.1186/bcr3242
  • Schuster, Cornelia; Eikesdal, Hans Petter; Puntervoll, Hanne Eknes; Geisler, Jürgen; Geisler, Stephanie; Heinrich, Daniel; Molven, Anders; Lønning, Per Eystein; Akslen, Lars A.; Straume, Oddbjørn. 2012. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension. PLOS ONE. 7. 8 sider. doi: 10.1371/journal.pone.0038364
  • Skotheim, Rolf Inge; Meza-Zepeda, Leonardo Andrés; Hovig, Eivind; Lønning, Per Eystein; Lothe, Ragnhild A; Myklebost, Ola. 2012. Genomsekvensering for persontilpasset kreftbehandling. Tidsskrift for Den norske legeforening. 132: 2406-2408. doi: 10.4045/tidsskr.12.0784
  • Straume, Anne Hege; Knappskog, Stian; Lønning, Per Eystein. 2012. Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology. 128: 69-75. doi: 10.1016/j.jsbmb.2011.08.015
  • Straume, Anne Hege; Løvås, Kristian; Miletic, Hrvoje; Gravdal, Karsten; Lønning, Per Eystein; Knappskog, Stian. 2012. Elevated levels of the steroidogenic factor 1 are associated with over-expression of CYP19 in an oestrogen-producing testicular Leydig cell tumour. European Journal of Endocrinology. 166: 941-949. doi: 10.1530/EJE-11-0849
  • Ånensen, Nina; Hjelle, Sigrun Margrethe; Van, Belle Werner; Haaland, Ingvild; Silden, Elisabeth; Bourdon, Jean-Christophe; Hovland, Randi; Tasken, Kjetil; Knappskog, Stian; Lønning, Per Eystein; Bruserud, Øystein; Gjertsen, Bjørn Tore. 2012. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 31: 1533-1545. doi: 10.1038/onc.2011.348
  • Akslen, Lars A.; Straume, Oddbjørn; Geisler, Stephanie; Sørlie, Therese; Chi, Jen-Tan Ashley; Aas, Turid; Børresen-Dale, Anne-Lise; Lønning, Per Eystein. 2011. Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancer. British Journal of Cancer. 105: 9-12. doi: 10.1038/bjc.2011.203
  • Berge, Elisabet Ognedal; Knappskog, Stian; Lillehaug, Johan R.; Lønning, Per Eystein. 2011. Alterations of the retinoblastoma gene in metastatic breast cancer. Clinical and Experimental Metastasis. 28: 319-326. doi: 10.1007/s10585-011-9375-y
  • Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Skjønsberg, Gudbrand; Aas, Turid; Schlichting, Ellen; Fjøsne, Hans Erikssønn; Nysted, Arne; Lillehaug, Johan R.; Lønning, Per Eystein. 2011. Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. PLOS ONE. 6. 10 sider. doi: 10.1371/journal.pone.0019249
  • Dowsett, Mitch; Lønning, Per Eystein. 2011. Special Issue 10th International Aromatase Conference Proceedings, September 2010 Preface. Steroids. 76: 729-729. doi: 10.1016/j.steroids.2011.03.003
  • Fjøsne, Hans Erikssønn; Søreide, Jon Arne; Kåresen, Rolf; Lønning, Per Eystein; Jacobsen, Anne-Birgitte; Lundgren, Steinar. 2011. Hospital volume and prognosis among Norwegian breast cancer patients enrolled in adjuvant trials. Acta Oncologica. 50: 1068-1074. doi: 10.3109/0284186X.2011.585998
  • Knappskog, Stian; Bjørnslett, Merete Pauline; Myklebust, Line Merethe; Huijts, Petra E.A.; Vreeswijk, Maaike P.; Edvardsen, Hege; Guo, Yongli; Zhang, Xuemei; Yang, Ming; Ylisaukko-oja, Sanna K.; Alhopuro, Pia; Arola, Johanna; Tollenaar, Rob A.E.M.; van Asperen, Christi J; Seynaeve, Caroline; Staalesen, Vidar; Chrisanthar, Ranjan; Løkkevik, Erik; Salvesen, Helga Birgitte; Evans, D. Gareth; Newman, William G.; Lin, Dongxin; Aaltonen, Lauri; Børresen-Dale, Anne-Lise; Tell, Grethe S; Stoltenberg, Camilla; Romundstad, Pål Richard; Hveem, Kristian; Lillehaug, Johan R.; Vatten, Lars Johan; Devilee, Peter; Dørum, Anne; Lønning, Per Eystein. 2011. The MDM2 Promoter SNP285C/309G Haplotype Diminishes Sp1 Transcription Factor Binding and Reduces Risk for Breast and Ovarian Cancer in Caucasians. Cancer Cell. 19: 273-282. doi: 10.1016/j.ccr.2010.12.019
  • Knappskog, Stian; Lønning, Per Eystein. 2011. MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. OncoTarget. 2: 251-258.
  • Knappskog, Stian; Lønning, Per Eystein. 2011. Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription. doi: 10.4161/trns.2.5.16813
  • Knappskog, Stian; Myklebust, Line Merethe; Busch, Christian; Aloysius, Thomas Aquinas; Varhaug, Jan Erik; Lønning, Per Eystein; Lillehaug, Johan R.; Pendino, Frederic. 2011. RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer(dagger). Annals of Oncology. 22: 2208-2215. doi: 10.1093/annonc/mdq737
  • Lønning, Per Eystein. 2011. The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology. 22: 503-514. doi: 10.1093/annonc/mdq337
  • Lønning, Per Eystein; Haynes, Ben P.; Straume, Anne Hege; Dunbier, Anita; Helle, Hildegunn; Knappskog, Stian; Dowsett, Mitch. 2011. Recent data on intratumor estrogens in breast cancer. Steroids. 76: 786-791. doi: 10.1016/j.steroids.2011.02.040
  • Lønning, Per Eystein; Haynes, Ben P.; Straume, Anne Hege; Dunbier, Anita; Helle, Hildegunn; Knappskog, Stian; Dowsett, Mitch. 2011. Exploring breast cancer estrogen disposition: The basis for endocrine manipulation. Clinical Cancer Research. 17: 4948-4958. doi: 10.1158/1078-0432.CCR-11-0043
  • Berge, Elisabet Ognedal; Knappskog, Stian; Geisler, Stephanie; Staalesen, Vidar; Pacal, Marec; Børresen-Dale, Anne-Lise; Puntervoll, Pål; Lillehaug, Johan R.; Lønning, Per Eystein. 2010. Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers. Molecular Cancer. 9. 13 sider. doi: 10.1186/1476-4598-9-173
  • Berge, Elisabet Ognedal; Staalesen, Vidar; Straume, Anne Hege; Lillehaug, Johan R.; Lønning, Per Eystein. 2010. Chk2 splice variants express a dominant-negative effect on the wild-type Chk2 kinase activity. BBA - Molecular Cell Research. 1803: 386-395. doi: 10.1016/j.bbamcr.2010.01.005
  • Busch, Christian; Geisler, Jürgen; Knappskog, Stian; Lillehaug, Johan R.; Lønning, Per Eystein. 2010. Alterations in the p53 Pathway and p16INK4a Expression Predict Overall Survival in Metastatic Melanoma Patients Treated with Dacarbazine. Journal of Investigative Dermatology. 130: 2514-2516. doi: 10.1038/jid.2010.138
  • Busch, Christian; Geisler, Jürgen; Lillehaug, Johan R.; Lønning, Per Eystein. 2010. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC. European Journal of Cancer. 46: 2127-2133. doi: 10.1016/j.ejca.2010.04.023
  • Dejeux, Emelyne; Rønneberg, Jo Anders; Solvang, Hiroko Kato; Bukholm, Ida R. K.; Geisler, Stephanie; Aas, Turid; Gut, Ivo G.; Børresen-Dale, Anne-Lise; Lønning, Per Eystein; Kristensen, Vessela Nedelcheva; Tost, Jörg. 2010. DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response. Molecular Cancer. 9. 13 sider. doi: 10.1186/1476-4598-9-68
  • Geisler, Jurgen; Lønning, Per Eystein. 2010. Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology. 118: 294-299. doi: 10.1016/j.jsbmb.2009.10.004
  • Geisler, Jurgen; Suzuki, Takashi; Helle, Hildegunn; Miki, Yasuhiro; Nagasaki, Shuji; Duong, Nhat Kim; Ekse, Dagfinn; Aas, Turid; Evans, Dean B.; Lønning, Per Eystein; Sasano, Hironobu. 2010. Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology. 118: 237-241. doi: 10.1016/j.jsbmb.2009.10.010
  • Haynes, Ben P.; Straume, Anne Hege; Geisler, Jurgen; A'Hern, Roger; Helle, Hildegunn; Smith, Ian E; Lønning, Per Eystein; Dowsett, Mitch. 2010. Intratumoral estrogen disposition in breast cancer. Clinical Cancer Research. 16: 1790-1801. doi: 10.1158/1078-0432.CCR-09-2481
  • Jönsson, Göran; Busch, Christian; Knappskog, Stian; Geisler, Jürgen; Miletic, Hrvoje; Ringnér, Markus; Lillehaug, Johan R.; Borg, Åke; Lønning, Per Eystein. 2010. Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome. Clinical Cancer Research. 16: 3356-3367. doi: 10.1158/1078-0432.CCR-09-2509
  • Lønning, Per Eystein. 2010. Exploring chemoresistance in vivo; are we making progress. European Journal of Cancer. 8: 155-155.
  • Lønning, Per Eystein. 2010. Molecular basis for therapy resistance. Molecular Oncology. 4: 284-300. doi: 10.1016/j.molonc.2010.04.005
  • Lønning, Per Eystein. 2010. Are current development programs realising the full potential of new agents? Breast Cancer Research. 12. 4 sider. doi: 10.1186/bcr2752
  • Lønning, Per Eystein. 2010. Evolution of endocrine adjuvant therapy for early breast cancer. Expert Opinion on Investigational Drugs. 19: S19-S30. doi: 10.1517/13543781003714865
  • Lønning, Per Eystein. 2010. Are current development programs realising the full potential of new agents? Breast Cancer Research. 12: s23-s26. doi: 10.1186/bcr2752
  • Lønning, Per Eystein; Geisler, Jürgen. 2010. Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding? Journal of Steroid Biochemistry and Molecular Biology. 118: 288-293. doi: 10.1016/j.jsbmb.2009.09.013
  • Mouridsen, Henning T; Lønning, Per Eystein; Beckmann, Matthias W; Blackwell, Karen; Doughty, Julie; Gligorov, Joseph; Llombart-Cussac, Antonio; Robidoux, Andre; Thurlimann, Beat; Gnant, Michael. 2010. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer. Expert Review of Anticancer Therapy. 10: 1825-1836. doi: 10.1586/ERA.10.160
  • Robertson, John; Lønning, Per Eystein. 2010. Session 6 introduction. Breast Cancer Research. 12. 3 sider. doi: 10.1186/bcr2744
  • Torsvik, Anja; Røsland, Gro Vatne; Svendsen, Agnete; Molven, Anders; Immervoll, Heike; McCormack, Emmet Martin; Lønning, Per Eystein; Primon, Monica; Sobala, Ewa; Tonn, Jörg Christian; Goldbrunner, Roland; Schichor, Christian; Mysliwietz, Josef; Lah, Tamara; Motaln, Helena; Knappskog, Stian; Bjerkvig, Rolf. 2010. Spontaneous Malignant Transformation of Human Mesenchymal Stem Cells Reflects Cross-Contamination: Putting the Research Field on Track - Letter. Cancer Research. 70: 6393-6396. doi: 10.1158/0008-5472.CAN-10-1305
  • Christoffersen, Thoralf; Guren, Tormod K.; Spindler, Karen-Lise Garm; Dahl, Olav; Lønning, Per Eystein; Gjertsen, Bjørn Tore. 2009. Cancer therapy targeted at cellular signal transduction mechanisms: strategies, clinical results, and unresolved issues. European Journal of Pharmacology. 625: 6-22. doi: 10.1016/j.ejphar.2009.10.009
  • Flageng, MH; Hauglid, Marianne; Moi, Line Leonore Haugan; Dixon, J. Michael; Geisler, Jurgen; Lien, Ernst Asbjørn; Miller, William Russell; Lonning, PE; Lønning, Per Eystein; Mellgren, Gunnar. 2009. Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer. 101: 1253-1260. doi: 10.1038/sj.bjc.6605324
  • Glynn, Sharon A.; Boersma, Brenda J.; Howe, Tiffany M.; Edvardsen, Hege; Geisler, Stephanie; Goodman, Julie E.; Ridnour, Lisa A.; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Naume, Bjørn; Kristensen, Vessela Nedelcheva; Chanock, Stephen J.; Wink, David A.; Ambs, Stefan. 2009. A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide. Clinical Cancer Research. 15: 4165-4173. doi: 10.1158/1078-0432.CCR-09-0119
  • Hans, Volkmar; Evans, D; Evans, Dean B.; Lønning, Per Eystein; Geisler, Jurgen. 2009. Proteomics analysis of tissue samples obtained before and during letrozole treatment in postmenopausal patients with locally advanced breast cancer. Cancer Research. 69: 214S-214S.
  • Haynes, B; Straume, Anne Hege; Geisler, Jurgen; Ahern, R; Lønning, Per Eystein; Lonning, PE; Dowsett, M. 2009. DETERMINANTS OF INTRATUMOURAL OESTRADIOL (E2) CONCENTRATIONS IN POSTMENOPAUSAL BREAST CANCER: ROLES FOR OESTROGEN RECEPTOR (ER) AND 17B-HYDROXYSTEROID DEHYDROGENASE 7 (HSD17B7). Annals of Oncology. 20: 51-52.
  • Lønning, Per Eystein. 2009. Tailored targeted therapy for all: a realistic and worthwhile objective? Breast Cancer Research. 11. doi: 10.1186/bcr2426
  • Lønning, Per Eystein. 2009. Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation? European Journal of Cancer. 45: 527-535. doi: 10.1016/j.ejca.2008.10.019
  • Lønning, Per Eystein. 2009. Additive endocrine therapy for advanced breast cancer - back to the future. Acta Oncologica. 48: 1092-1101. doi: 10.3109/02841860903117816
  • Lønning, Per Eystein. 2009. Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports. 1: 183-189. doi: 10.1007/s12609-009-0026-0
  • Lønning, Per Eystein; Helle, Hildegunn; Duong, Nhat Kim; Ekse, Dagfinn; Aas, T; Geisler, Jurgen. 2009. Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology. 117: 31-41. doi: 10.1016/j.jsbmb.2009.06.005
  • Røsland, Gro Vatne; Svendsen, Agnete; Torsvik, Anja; Sobala, Ewa; McCormack, Emmet Martin; Immervoll, Heike; Mysliwietz, Josef; Tonn, Jörg Christian; Goldbrunner, Roland; Lønning, Per Eystein; Bjerkvig, Rolf; Schichor, Christian. 2009. Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. Cancer Research. 69: 5331-5339. doi: 10.1158/0008-5472.CAN-08-4630
  • Chekenya, Martha; Krakstad, Camilla; Svendsen, Agnete; Netland, Inger Anne; Staalesen, Vidar; Tysnes, Berit Bølge; Selheim, Frode; Wang, Jian; Sakariassen, Per Øystein; Sandal, Tone; Lønning, Per Eystein; Flatmark, Torgeir; Enger, Per Øyvind; Bjerkvig, Rolf; Sioud, M; Stallcup, William B. 2008. The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling. Oncogene. 27: 5182-5194. doi: 10.1038/onc.2008.157
  • Chrisanthar, Ranjan; Knappskog, Stian; Løkkevik, Erik; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Berge, Elisabet Ognedal; Risberg, Terje; Mjaaland, Ingvil; Mæhle, Lovise Olaug; Engebretsen, Lars Fredri; Lillehaug, Johan; Lønning, Per Eystein. 2008. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLOS ONE. 3:e0003062. 15 sider. doi: 10.1371/journal.pone.0003062
  • Geisler, Jurgen; Ekse, Dagfinn; Helle, Hildegunn; Duong, Nhat Kim; Lønning, Per Eystein. 2008. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology. 109: 90-95. doi: 10.1016/j.jsbmb.2007.12.011
  • Geisler, Jurgen; Helle, Hildegunn; Ekse, Dagfinn; Ekse, D.; Duong, Nhat Kim; Evans, Dean B.; Nordbø, Yngve; Aas, Turid; Lønning, Per Eystein. 2008. Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research. 14: 6330-6335. doi: 10.1158/1078-0432.CCR-07-5221
  • Gjerde, Jennifer Fernandez; Geisler, Jurgen; Lundgren, Steinar; Ekse, Dagfinn; Breilid, Harald; Hauglid, Marianne; Hauglid, M; Varhaug, EJ; Varhaug, Jan Erik; Steen, Vidar Martin; Lønning, Per Eystein; Lonning, PE; Lien, Ernst Asbjørn. 2008. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. 109: 592-592.
  • Lønning, Per Eystein. 2008. Endocrine therapy and bone loss in breast cancer. Time to close in the RANK(L)? Journal of Clinical Oncology. 26: 4859-4861. doi: 10.1200/JCO.2008.18.0851
  • Lønning, Per Eystein. 2008. Endocrine treatment - "old-fashioned" therapy becoming redundant in an era of molecular medicine? Breast Care. 3: 388-390.
  • Lønning, Per Eystein. 2008. Exploring the lack of cross-resistance between aromatase inhibitors: evidence for a difference? Anti-Cancer Drugs. 19: S11-S13.
  • Lønning, Per Eystein. 2008. Aromatase inhibition versus placebo. Clinical Breast Cancer. 8: 374-374.
  • Lønning, Per Eystein. 2008. ER/PGR and prediction of response to hormonotherapy. Can we do better? Annals of Oncology. 19: 29-29.
  • Lønning, Per Eystein. 2008. Are there any difference between third-generation aromatase inhibitors? European Journal of Cancer. 6: 52-52.
  • Lønning, Per Eystein. 2008. Strength and weakness of phase I-IV trials with emphasis on translational aspects. Breast Cancer Research. 10: 1-5. doi: 10.1186/bcr2182
  • Lønning, Per Eystein; Geisler, Jurgen. 2008. Indications and limitations of third-gene ration aromatase inhibitors. Expert Opinion on Investigational Drugs. 17: 723-739. doi: 10.1517/13543780802041751
  • Lønning, Per Eystein; Geisler, Jurgen. 2008. Experience with exemestane in the treatment of early and advanced breast cancer. Expert Opinion on Drug Metabolism & Toxicology. 4: 987-997. doi: 10.1517/17425250802204142
  • Lønning, Per Eystein; Geisler, Jurgen. 2008. Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology. 108: 196-202. doi: 10.1016/j.jsbmb.2007.09.017
  • Miller, William R.; Bartlett, John; Brodie, Angela MH; Brueggemeier, Robert W; Di Salle, Enrico; Lønning, Per Eystein; Llombart, Antonio; Maass, Nicolai; Maudelonde, Thierry; Sasano, Hironobu; Goss, Paul E. 2008. Aromatase inhibitors: Are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? The Oncologist. 13: 829-837. doi: 10.1634/theoncologist.2008-0055
  • Nordgard, Silje H.; Nordgard, Silje H.; Alnæs, Grethe I.G.; Alnaes, GIG; Hihn, Björn; Lingjærde, Ole Chr.; Liestøl, Knut; Tsalenko, Anya; Sørlie, Therese; Lønning, Per Eystein; Lonning, PE; Børresen-Dale, Anne-Lise; Kristensen, Vessela Nedelcheva. 2008. Pathway based analysis of SNPs with relevance to 5-FU therapy: Relation to intratumoral mRNA expression and survival. International Journal of Cancer. 123: 577-585. doi: 10.1002/ijc.23541
  • Rønneberg, Jo Anders; Tost, Jörg; Solvang, Hiroko K.; Alnaes, GIG; Alnæs, Grethe Irene Grenaker; Johansen, Fredrik E.; Brendeford, Ellen M.; Yakhini, Zohar; Gut, Ivo G.; Lonning, PE; Lønning, Per Eystein; Børresen-Dale, Anne-Lise; Gabrielsen, Odd Stokke; Kristensen, Vessela Nedelcheva. 2008. GSTP1 promoter haplotypes affect DNA methylation levels and promoter activity in breast carcinomas. Cancer Research. 68: 5562-5571. doi: 10.1158/0008-5472.CAN-07-5828
  • Busch, Christian; Geisler, Jurgen; Lillehaug, Johan R.; Lønning, Per Eystein. 2007. Promotor hypermethylation of MGMT, RAR-beta2, RASSF1A and p16 in metastatic malignant melanoma. Proceedings of the American Association of Cancer Research. 48: 684.
  • Chrisanthar, Ranjan; Knappskog, Stian; Staalesen, Vidar; Lillehaug, Johan; Lønning, Per Eystein. 2007. P21/waf1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. International Journal of Cancer. 120: 2749-2749. doi: 10.1002/ijc.22595
  • Coombes, R. Charles; Kilburn, Lucy S.; Snowdon, Claire F.; Paridaens, Robert; Coleman, Ronert E.; Jones, Stephen E.; Jassem, Jacek; Van de Velde, Cornelis J.H.; Delozier, Thierry; Álvarez, Inmaculada; Del Mastro, Lucia; Ortmann, Olaf; Diedrich, Klaus; Coates, Alan S.; Bajetta, Emilio; Holmberg, Stig B.; Dodwell, David; Mickiewicz, Elizabeth; Andersen, Jesper; Lønning, Per Eystein; Cocconi, Giorgio; Forbes, John; Castiglione, Monica; Stuart, Nick; Stewart, Alan; Fallowfield, Lesley J.; Bertelli, Gian; Hall, Emma; Bogle, Richard G.; Carpentieri, Mary; Colajori, Elena; Subar, Milayna; Ireland, Elizabeth; Bliss, Judith M. 2007. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. The Lancet. 369: 559-570. doi: 10.1016/S0140-6736(07)60200-1
  • Geisler, Jurgen; Haynes, Ben; Ekse, Dagfinn; Dowsett, Mitch; Lønning, Per Eystein. 2007. Total body aromatization in postmenopausal breast cancer patients is strongly correlated to plasma leptin levels. Journal of Steroid Biochemistry and Molecular Biology. 104: 27-34. doi: 10.1016/j.jsbmb.2006.09.040
  • Gjerde, Jennifer Fernandez; Geisler, Jurgen; Lundgren, Steinar; Ekse, Dagfinn; Breilid, Harald; Hauglid, Marianne; Varhaug, Jan Erik; Mellgren, Gunnar; Steen, Vidar Martin; Lønning, Per Eystein; Lien, Ernst Asbjørn. 2007. A study of associations between estrogen and tamoxifen metabolism, cytochrome 2D6 and sulfotransferase 1A1 polymorphisms, and sulfotransferase 1A1 gene copy number during steady state tamoxifen treatment. Breast Cancer Research and Treatment. S106.
  • Grudic, Amra; Jul-Larsen, Åsne; Haring, SJ; Wold, MS; Lønning, Per Eystein; Bjerkvig, Rolf; Bøe, Stig Ove. 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 35: 7267-7278. doi: 10.1093/nar/gkm738
  • Grudic, Amra; Jul-Larsen, Åsne; Haring, Stuart J.; Wold, Marc S.; Lønning, Per Eystein; Bjerkvig, Rolf; Bøe, Stig Ove. 2007. Replication protein A prevents accumulation of single-stranded telomeric DNA in cells that use alternative lengthening of telomeres. Nucleic Acids Research. 35: 7267-7278.
  • Knappskog, Stian; Chrisanthar, Ranjan; Staalesen, Vidar; Borresen-Dale, AL; Børresen-Dale, Anne-Lise; Gram, Inger Torhild; Lillehaug, Johan Richard; Lonning, PE; Lønning, Per Eystein. 2007. Mutations and polymorphisms of the p21B transcript in breast cancer. International Journal of Cancer. 121: 908-910. doi: 10.1002/ijc.22777
  • Lønning, Per Eystein. 2007. Adjuvant endocrine treatment of early breast cancer. Hematology/Oncology Clinics of North America. 21: 223-238. doi: 10.1016/j.hoc.2007.03.002
  • Lønning, Per Eystein. 2007. Biological lessons from adjuvant therapy. European Journal of Cancer. 5: 25-25. doi: 10.1016/S1359-6349(07)70199-4
  • Lønning, Per Eystein. 2007. Breast cancer prognostication and prediction: are we making progress? Annals of Oncology. 18: viii3-viii7. doi: 10.1093/annonc/mdm260
  • Lønning, Per Eystein; Chrisanthar, Ranjan; Staalesen, Vidar; Knappskog, Stian; Lillehaug, Johan. 2007. Adjuvant treatment: the contribution of expression microarrays. Breast Cancer Research. 9. doi: 10.1186/bcr1812
  • Lønning, Per Eystein; Geisler, Jurgen. 2007. Aromatase inhibitors-Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology. 106: 55-61. doi: 10.1016/j.jsbmb.2007.05.002
  • Lønning, Per Eystein; Knappskog, Stian; Staalesen, Vidar; Chrisanthar, Ranjan; Lillehaug, Johan. 2007. Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology. 18: 1293-1306. doi: 10.1093/annonc/mdm013
  • Nordgard, Silje H.; Nordgard, Silje H.; Ritchie, Marylyn D.; Jensrud, Sigrid D.; Motsinger, Alison A.; Alnæs, Grethe I.G.; Alnaes, GIG; Lernmon, Gordon; Berg, Marianne; Gelsler, S; Geisler, Stephanie; Moore, Jason H.; Lønning, Per Eystein; Lonning, PE; Børresen-Dale, Anne-Lise; Kristensen, Vessela Nedelcheva. 2007. ABCB1 and GST polymorphisms associated with TP53 status in breast cancer. Pharmacogenetics & Genomics. 17: 127-136.
  • Norum, Jan; Olsen, Jan Abel; Wist, Erik; Lønning, Per Eystein; Lonning, PE. 2007. Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta Oncologica. 46. doi: 10.1080/02841860601096841
  • Baumbusch, Lars Oliver; Myhre, Simen; Langerød, Anita; Bergamaschi, Anna; Geisler, Stephanie B; Lønning, Per Eystein; Deppert, Wolfgang; Dornreiter, Irene; Børresen-Dale, Anne-Lise. 2006. Expression of full-length p35 and its isoform DELTAp53 in breast carcinomas in relation to mutation status and clinical parameters. Molecular Cancer. 5: 47. doi: 10.1186/1476-4598-5-47
  • Bøe, Stig Ove; Haave, Marte; Jul-Larsen, Åsne; Grudic, Amra; Bjerkvig, Rolf; Lønning, Per Eystein. 2006. Promyelocytic leukemia nuclear bodies are predetermined processing sites for damaged DNA. Journal of Cell Science. 119: 3284-3295. doi: 10.1242/jcs.03068
  • Geisler, J; Lønning, Per Eystein; Krag, LE; Løkkevik, Erik; Løkkevik, Erik; Risberg, Terje; Hagen, AI; Schlichting, E; Lien, EA; Ofjord, ES; Øfjord, Erik S.; Eide, GE; Di Salle, Enrico; Polli, A; di Salle, E; Paolini, J. 2006. Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 42: 2968-75.
  • Geisler, Jürgen; Lønning, Per Eystein. 2006. Aromatase inhibitors as adjuvant treatment of breast cancer. Critical Reviews in Oncology/Hematology. 57: 53-61.
  • Huszthy, Peter Csaba; Brekken, Christian; Pedersen, Tina Bugge; Thorsen, Frits Alan; Sakariassen, Per Øystein; Skaftnesmo, Kai Ove; Haraldseth, Olav; Lønning, Per Eystein; Lonning, PE; Bjerkvig, Rolf; Enger, Per Øyvind. 2006. Antitumor efficacy improved by local delivery of species-specific endostatin. Journal of Neurosurgery. 104: 118-128.
  • Knappskog, Stian; Geisler, Jürgen; Arnesen, Thomas; Lillehaug, Johan; Lønning, Per Eystein. 2006. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. Genes, Chromosomes and Cancer. 45: 1155-1163. Publisert 2006-09-25. doi: 10.1002
  • Knudsen, Anette; Monstad, Sissel Evy; Dørum, Anne; Lønning, Per Eystein; Salvesen, Helga; Drivsholm, Lars; Aarseth, Jan Harald; Vedeler, Christian A. 2006. Ri antibodies in patients with breast, ovarian or small cell lung cancer determined by a sensitive immunoprecipitation technique. Cancer Immunology and Immunotherapy. 55: 1280-1284. doi: 10.1007/s00262-006-0121-2
  • Kristensen, Vessela N.; Edvardsen, Hege; Tsalenko, Anya; Nordgard, Silje H.; Sørlie, Therese; Sharan, Roded; Vailaya, Aditya; Ben-Dor, Amir; Lønning, Per Eystein; Lien, Sigbjørn; Omholt, Stig W.; Syvänen, Ann-Christine; Yakhini, Zohar; Børresen-Dale, Anne-Lise. 2006. Genetic variation in putative regulatory loci controlling gene expression in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 103: 7735-7740.
  • Lønning, Per Eystein. 2006. Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology. 17: 217-225. doi: 10.1093/annonc/mdj048
  • Lønning, Per Eystein; Geisler, Jürgen. 2006. Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 3: 356-367.
  • Lønning, Per Eystein; Geisler, Jürgen. 2006. Commentary on: Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer? Nature Clinical Practice Oncology. 3: 356-357.
  • Monstad, Sissel Evy; Storstein, Anette Margrethe; Dørum, Anne; Knudsen, Anette; Lønning, Per Eystein; Salvesen, Helga; Aarseth, Jan Harald; Vedeler, Christian A. 2006. Yo antibodies in ovarian and breast cancer patients detected by a sensitive immunoprecipitation technique. Clinical and Experimental Immunology. 144: 53-58. doi: 10.1111/j.1365-2249.2006.03031
  • Muggerud, Aslaug Aamodt; Johnsen, Hilde; Barnes, Debra A.; Steel, Adam; Lønning, Per Eystein; Lonning, PE; Sørlie, Therese; Naume, Bjørn; Børresen-Dale, Anne-Lise. 2006. Evaluation of MetriGenix custom 4D (TM) arrays applied for detection of breast cancer subtypes. BMC Cancer. 6. 6 sider. doi: 10.1186/1471-2407-6-59
  • Staalesen, Vidar; Stålesen, Vidar; Knappskog, Stian; Chrisanthar, Ranjan; Nordgard, Silje H; Nordgard, Silje H.; Løkkevik, Erik; Anker, Gun; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjåland, Ingvil; Mjaaland, Ingvil; Gram, Inger Torhild; Kristensen, Vessela N; Børresen-Dale, Anne-Lise; Lillehaug, Johan Richard; Lønning, Per Eystein. 2006. The novel p21 polymorphism p21(G251A) is associated with locally advanced breast cancer. Clinical Cancer Research. 12: 6000-6004.
  • Sørlie, Therese; Perou, Charles M.; Fan, Cheng; Geisler, Stephanie; Aas, Turid; Nobel, Andrew; Anker, Gun; Akslen, Lars A.; Botstein, David; Børresen-Dale, Anne-Lise; Lønning, Per Eystein. 2006. Gene expression profiles do not consistently predict the clinical treatment response in locally advanced breast cancer. Molecular Cancer Therapeutics. 5: 2914-2918. doi: 10.1158/1535-7163.MCT-06-0126
  • Thorsen, Frits Alan; Afione, Sandra; Huszthy, Peter Csaba; Tysnes, Berit Bølge; Svendsen, Agnete; Bjerkvig, Rolf; Kotin, Robert M.; Lønning, Per Eystein; Hoover, Frank. 2006. Adeno-associated virus (AAV) serotypes 2, 4 and 5 display similar transduction profiles and penetrate solid tumor tissue in models of human glioma. Journal of Gene Medicine. 8: 1131-1140. doi: 10.1002/jgm.939
  • Aas, Turid; Geisler, Stephanie; Helle, Hildegunn; Børresen-Dale, Anne-Lise; Lønning, Per Eystein; Akslen, Lars Andreas. 2005. Prognostic and predictive value of changes in tumour cell proliferation in locally advanced breast cancer primarily treated with doxorubicin. Oncology Reports. 13: 525-530.
  • Come, SE; Buzdar, AU; Ingle, JN; Arteage, CL; Brodie, AM; Colditz, GA; Johnston, SRD; Kristensen, VN; Lønning, Per Eystein; Mcdonnell, DP; Osborne, CK; Russo, J; Santen, RJ; Yee, D; Hart, C. 2005. Proceedings of the fourth international conference on recent advances and future directions in endocrine therapy for breast cancer: Conference summary statement. Clinical Cancer Research. 11: 861-864.
  • Jeffrey, SS; Lønning, Per Eystein; Hillner, BE. 2005. Genomics-based prognosis and therapeutic prediction in breast cancer. The Journal of the National Comprehensive Cancer Network. 3: 291-300.
  • Joensuu, Heikki; Ejlertsen, Bent; Lønning, Per Eystein; Rutqvist, Lars-Erik. 2005. Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta Oncologica. 44: 23-31. doi: 10.1080/02841860510007468
  • Kristensen, Vessela N.; Sørlie, Therese; Geisler, Jurgen; Langerød, Anita; Yoshimura, Noriko; Kåresen, Rolf; Harada, Nobuhiro; Lønning, Per Eystein; Børresen-Dale, Anne-Lise. 2005. Gene expression profiling of breast cancer in relation to estrogen receptor status and estrogen-metabolizing enzymes: Clinical implication. Clinical Cancer Research. 11: 878s-883s.
  • Kristensen, Vessela Nedelcheva; Sørlie, Therese; Sorlie, Therese; Geisler, Jürgen; Geisler, E; Yoshimura, Noriko; Lingjærde, Ole Christian; Linegjaerde, Ole-Christian; Glad, Ingrid; Frigessi, Arnoldo; Harada, Nobuhiro; Lonning, PE; Lønning, Per Eystein; Børresen-Dale, Anne-Lise. 2005. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer. Journal of Steroid Biochemistry and Molecular Biology. 95: 105-111. doi: 10.1016/j.jsbmb.2005.04.028
  • Lønning, Per Eystein. 2005. Aromatasehemmere i behandling av brystkreft. Tidsskrift for Den norske legeforening. 125: 723-728.
  • Lønning, Per Eystein; Geisler, Jürgen. 2005. Aromatase inhibitors - socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology. 95: 137-142. doi: 10.1016/j.jsbmb.2005.04.006
  • Lønning, Per Eystein; Sørlie, T; Børresen-Dale, Anne-Lise. 2005. Genomics in breast cancer - therapeutic implications? Nature Clinical Practice Oncology. 2: 26-33.
  • Staalesen, Vidar; Knappskog, Stian; Geisler, Stephanie; Baumbusch, L; Børresen-Dale, Anne-Lise; Lillehaug, Johan; Lønning, Per Eystein; Lonning, PE. 2005. The SNP309HDM2 polymorphism is associated with chemoresistance and poor survival in breast cancers harboring mutations in the TP53 gene. Breast Cancer Research and Treatment. 94: S160-S160.
  • Coombes, R. Charles; Hall, Emma; Gibson, Lorna J.; Paridaens, Robert; Jassem, J; Delozier, T; Jones, S; Alvarez, I; Bertelli, G; Ortman, O; Coates, AS; Bajetta, E; Dodwell, D; Coleman, RE; Fallowfield, LJ; Mickiewicz, E; Andersen, J; Lønning, Per Eystein; Coocconi, C; Stewart, A; Stuart, N; Snowdon, CF; Carpentieri, M; Massimini, G; Bliss, JM. 2004. Exemestane improves disease-free survival in postmenopausal patients with early breast cancer after two to three years of tamoxifen: a double blind study. New England Journal of Medicine. 350: 1081-1092.
  • Jul-Larsen, Åsne; Jul-Larsen, A; Visted, T; Karlsen, BO; Rinaldo, Christine H; Bjerkvig, R; Lonning, PE; Lønning, Per Eystein; Boe, SO; Bøe, Stig Ove. 2004. PML-nuclear bodies accumulate DNA in response to polyomavirus BK and simian virus 40 replication. Experimental Cell Research. 298: 58-73.
  • Lien, Ernst Asbjørn; Ueland, Per Magne; Lønning, Per Eystein. 2004. Letter. Journal of the National Cancer Institute. 96: 883-883.
  • Lønning, Per Eystein. 2004. Aromatase inhibitors in breast cancer. Endocrine-Related Cancer. 11: 179-189.
  • Lønning, Per Eystein. 2004. Genes causing inherited cancer as beacons to identify the mechanism of chemoresistance. Trends in Molecular Medicine. 10: 113-118.
Rapporter/avhandlinger
  • Johansen, Karianne; Lønning, Per Eystein; Naume, Bjørn; Norderhaug, Inger Natvig; Norum, Jan; Olsen, Jan Abel; Wist, Erik. 2006. Ny medikamentell behandling av brystkreft. Adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft. Rapport 2/2006. Nasjonalt kunnskapssenter for helsetjenesten, Oslo. 55 sider.
  • Johansen, Karianne; Lønning, Per Eystein; Naume, Bjørn; Norderhaug, Inger Natvig; Norum, Jan; Olsen, Jan Abel; Wist, Erik. 2006. Ny medikamentell behandling av brystkreft Adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft. Nasjonalt kunnskapssenter for helsetjenesten. 55 sider.
  • Johansen, Karianne; Lønning, Per Eystein; Naume, Bjørn; Norderhaug, Inger Natvig; Norum, Jan; Olsen, Jan Abel; Wist, Erik. 2006. Ny medikamentell behandling av brystkreft. Adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft. Rapport fra Kunnskapssenteret. 2/2006. Nasjonalt kunnskapssenter for helsetjenesten, Oslo. 55 sider.
  • Johansen, Karianne; Wisløff, Torbjørn; Kristiansen, Ivar Sønbø; Lønning, Per Eystein; Naume, Bjørn; Norum, Jan; Norderhaug, Inger Natvig; Olsen, Jan Abel; Wist, Erik. 2006. Ny medikamentell behandling av brystkreft Adjuvant behandling med trastuzumab ved tidlig stadium av brystkreft - en helseøkonomisk analyse. Rapport fra Kunnskapssenteret. 18. Nasjonalt kunnskapssenter for helsetjenesten, Oslo. 39 sider.
Bokkapitler
  • Geisler, Jürgen; Lønning, Per Eystein. 2006. Clinical pharmacology of aromatase inhibitors. 3, sider 45-52. I:
    • Furr, BJA. 2006. Milestones in Drug Therapy: Aromatase Inhibitors. Birkhäuser Verlag. 182 sider. ISBN: 3764371994.
  • Lønning, Per Eystein. 2005. Anti-endocrine drugs used in cancer treatment. 15, sider 216-237. I:
    • Schellens, JHM; McLeod, HL; Newell, DR. 2005. Cancer Clinical Pharmacology. Oxford University Press. 267 sider. ISBN: 0192629662.
  • Lønning, Per Eystein. 2005. Chemosensitization. 22, sider 335-348. I:
    • Curiel, David T.; Douglas, Joanne T. 2005. Cancer Gene Therapy. Humana Press. 489 sider. ISBN: 1-58829-213-4.

Se fullstendig oversikt over publikasjoner i CRIStin.

Kompetansefelt